Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stromal cells for traumatic brain injury
2024-516510-38-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
- Start
- Jan 2025
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing Mesenchymal stromal cells with Placebo (2 arms). Primary endpoints: Safety - serious adverse drug reactions, Biological activity - responder rate and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
Provacel
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2024-516510-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516510-38-00.